newsfilter
← Latest News
GlobeNewswire·

Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR) PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced